Copaxone Patent Suit: Is Teva Really Sure It Wants To Win The Case?
The bench trial in Teva Pharmaceutical USA Inc.'s Copaxone (glatiramer) patent infringement suit against Mylan Pharmaceuticals Inc. and Sandoz Inc. concluded on Sept. 21 and the parties now await a decision by the judge. If Teva is successful, it may end up asking itself what a victory in this patent battle would cost in the broader war on biosimilars.
You may also be interested in...
Sandoz, which has first to file on the generic, may have the most to lose after federal judge finds that Mylan and Sandoz ANDAs for generic Copaxone infringe all the claims in Teva’s patents, the latest of which expires in September 2015. FDA now has more time to review the ANDAs without pressure.
Teva’s new CEO, Jeremy Levin, has been emphasizing manufacturing efficiency, global compliance and a more focused R&D structure in initial comments to Wall Street.
At a Feb. 21 investor day, Mylan discussed its long-term goals for launching several biosimilars, as well some hard-to-reproduce generic offerings.